Infectious Diseases | Page 30 of 33

Dental Health :: Oragenics reports positive clinical results with its oral probiotic mouthrinse

Oragenics, Inc. (Amex: ONI) announced today that the first of two sets of subjects has completed a clinical trial utilizing its proprietary oral probiotic product, Probiora3(TM). The trial was designed to determine safety and the effectiveness of the mouthrinse against baseline levels of disease-causing bacteria in the mouth. Daily mouth rinsing with Probiora3(TM) resulted in substantial reductions in the numbers of the bacterium, S. mutans, which attacks teeth, as well as two target periodontal strains, Porphyromonas gingivalis and Campylobacter rectus, associated with gum disease and bad breath. The product was well tolerated by the subjects and no safety issues were identified with the twice daily use of the product over a two-month period.

Health :: MassTag PCR – new tool helps identify mysterious viruses – respiratory infection

A fast, sensitive and inexpensive diagnostic tool called MassTag PCR has been developed that can identify the specific pathogen that causes a particular case of respiratory infection, according to a new study funded by the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health (NIH). The research team ? headed by scientists in the Jerome L. and Dawn Greene Infectious Disease Laboratory at the Columbia University Mailman School of Public Health and their colleagues at the Wadsworth Center of the New York State Department of Health ? used MassTag PCR to identify previously undiagnosed pathogens that caused influenza-like illnesses in New York State during the winter of 2004.

HIV :: NIAID Announces New Campaign To Raise Awareness of Preventive HIV Vaccine Research

The National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, today announced the launch of the ?Be The Generation? public awareness campaign, challenging young Americans to be the generation that ends AIDS through the discovery of a safe and effective preventive HIV vaccine.

Allergy :: Experimental Ragweed Therapy Offers Allergy Sufferers Longer Relief with Fewer Shots

Americans accustomed to the seasonal misery of sneezing, runny noses and itchy, watery eyes caused by ragweed pollen might one day benefit from an experimental allergy treatment that not only requires fewer injections than standard immunotherapy, but leads to a marked reduction in symptoms that persists for at least a year after therapy has stopped, according to a new study in the October 5 issue of The New England Journal of Medicine (NEJM). The research was sponsored by the Immune Tolerance Network, which is funded by the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), both components of the National Institutes of Health (NIH), and the Juvenile Diabetes Research Foundation International.

Irritable Bowel Syndrome :: Traveller’s diarrhoea may raise risk of IBS

People who experience traveller’s diarrhoea appear to be at significantly increased risk of subsequently suffering from irritable bowel syndrome (IBS), a condition characterised by abdominal pain, bloating, diarrhoea, and constipation.

Imaging :: Tripath imaging receives fda 510(k) clearance for p53 application for ventana image analysis system

TriPath Imaging Inc. (Nasdaq: TPTH) and Ventana Medical Systems, Inc. (Nasdaq: VMSI), announced today that TriPath Imaging has received 510(k) clearance from the U.S. Food and Drug Administration for the Ventana Image Analysis System (VIAS(TM)) when used with tissues stained for p53. In 2005 and 2006, the Companies announced 510(k) clearances for VIAS when used with the Ventana Estrogen Receptor (ER), Progesterone Receptor (PR), Ki-67 and HER- 2/neu assays.

Nutrition :: Researchers look to solve mystery behind egcg and probiotics

When talking about nutrition, EGCG and probiotics are two words that we’ve been hearing a lot about these days. But most consumers don’t know what they are, where they are found and what they do. Some of that mystery was cleared up this week at the 47th Annual Symposia of the American College of Nutrition (ACN) where leading nutrition experts revealed new research about the health benefits of these two ingredients.

Health :: Reduce Methamphetamine Abuse

New research supported in part by the National Institute on Drug Abuse (NIDA), National Institutes of Health, shows that prevention programs conducted in middle school can reduce methamphetamine abuse among rural adolescents years later. Because methamphetamine addiction leads to problems with social interactions and a wide range of medical conditions, research into early interventions such as this is critical to protecting the nation?s youth. The paper is published in the September issue of Archives of Pediatrics and Adolescent Medicine.

Breast Implants :: Disease conditions related to breast implants

Some women with breast implants have reported health problems that they believe are related to their implants, but most studies of these diseases have failed to show an association with breast implants.

Tuberculosis :: How Promising TB Drug Works

Scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have determined how a promising drug candidate attacks the bacterium that causes tuberculosis (TB). Published online this week in Proceedings of the National Academy of Sciences, the finding may help scientists optimize the drug candidate, PA-824, which targets Mycobacterium tuberculosis (M. tb).